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Therapeutic efficacy of the non-peptide AVP antagonist OPC-31260 in
cirrhotic rats. The present study was undertaken to determine whether
a non-peptide arginine vasopressin (AVP) antagonist [5-dimethylamino-
1-{4-(2-methylbenzoylamino)benzoyl}-2,3,4,5-tetrahydro-1H-benzaze-
pine] (OPC-31260) improves the impaired water excretion in rats with
experimental liver cirrhosis. Male Wistar rats weighing 200 to 250 g
were injected in an equal volume (4 mI/kg) of carbon tetrachloride and
olive oil at an interval of seven days for three months, causing liver
cirrhosis with ascites. Control rats were injected with only olive oil.
Body weight (body wt) and hematocrit (Hct) were lower in the cirrhotic
rats than the control rats (body wt 360.7 vs. 238.5 g, P < 0.01; Hct 46.3
vs. 39.2%, P < 0.01). A water loading test (30 mI/kg) was carried out
and 20-minute urine collections were made for three hours. The percent
of water load excreted was 62.5% in the cirrhotic rats, a value
significantly less than that of 102. 1% in the control rats. However, its
percent increased to 215.1% after the oral administration of 5 mg/kg
OPC-31260 (P < 0.01). Minimal urinary osmolality (U0sm) was 185.5
mOsm/kg H20 in the cirrhotic rats receiving the vehicle, a value greater
than the control rats of 125.5 mOsm/kg H20 (P < 0.01). The oral
administration of 5 mg/kg OPC-3 1260 reduced minimal Uosm to 85.2
mOsm/kg H20 in the cirrhotic rats (P < 0.01). Urinary excretion of
sodium was lower in the cirrhotic rats than the control rats (87.1 vs.
312.4 Eq/3 hr, P < 0.01). The cirrhotic rats had lower GFR than the
controls (2.2 vs. 2.9 mI/mm, P < 0.05). Plasma AVP levels in the
cirrhotic rats were 4.2 pg/mI, a value greater than the control rats of 1.7
pg/mi (P < 0.01). Plasma AVP levels were reduced to 2.4 pg/mI in the
cirrhotic rats 60 minutes after the water load, while they were sup-
pressed to 0.9 pg/mI in the control rats. These results indicate that the
unsuppressible secretion of AVP is involved in the impaired water
excretion in the cirrhotic rats and that the orally effective, non-peptide
AVP antagonist OPC-3l260 is an effective therapeutic for the water
retention in decompensated liver cirrhosis.
Impaired ability to excrete a water load occurs in the patients
with decompensated state of liver cirrhosis [1—12] and experi-
mental models of liver dysfunction [13—18]. The elevation of
plasma arginine vasopressin (AVP) was found in such states of
liver dysfunction despite of hypoosmolality, which should
suppress plasma AVP to undetectable level in normal humans
and animals [2—5, 7, 13, 15, 16]. The nonosmotic release of AVP
has also been implicated as an important factor in the abnormal
water etabolism in patients and experimental rats with liver
cirrhosis [2, 3, 5, 8—10, 16.—18].
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Until recently, numerous efforts to design antagonists of the
AVP analogues have been made by Manning, Sawyer and their
associates [19—24]. These antagonists antagonize the anti-
diuretic effect of AVP in normal rats and during pathological
states of water retention [25—34]. However, they are difficult to
use clinically; they are V1V2 antagonists, but not pure V2
antagonist and are limited in parenteral use. Chronically admin-
istered AVP analogues lose their antagonism to the antidiuretic
effect of AVP and rather show the agonistic effect of AVP
[35—38]. There are also species differences in the antagonistic
effect of the AVP analogues on the antidiuretic action of AVP
[39]. This is a serious problem, because the AVP analogues
cannot antagonize in monkeys and humans.
Yamamura et al [401 have recently developed a newly syn-
thesized, orally effective, non-peptide AVP antagonist, 5-di-
methylamino-1-{4-(2-methylbenzoylamino)benzoyl}-2,3,4,5-tetra-
hydro-1H-benzazepine (OPC-3 1260), which blocks the binding
of AVP to plasma membrane of the kidney in a competitive
manner. We have already demonstrated the in vivo diuretic
effect of OPC-3 1260 in conscious rats [41] and the therapeutic
efficacy of OPC-3 1260 in syndrome of inappropriate secretion of
ADH (SIADH) produced by subcutaneous administration of
1-deamino-8-D-arginine vasopressin (dDAVP) and liquid diet
[42]. In the latter study, the repetitive dosing of 5 mg/kg
OPC-3 1260 remained effective at inducing water diuresis in the
experimental SIADH rats during at least a seven-day observa-
tion period, and kept serum Na level normal. Therefore, there
is no tachyphylaxis of OPC-3 1260 [42].
The present study was undertaken to determine whether the
non-peptide AVP antagonist OPC-3 1260 improves the impaired
water excretion in cirrhotic rats. Also, we compared the ther-






Male Wistar rats weighing 200 to 250 g were used in the
present study. The rats were injected with a mixture of carbon
tetrachloride (CC14) and olive oil (1:1, vollvol) subcutaneously
in a volume of 4.0 mllkg under light ether anesthesia at an
interval of seven days for three months. Body weight was
measured each time. After the 10th injection of the mixture of
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CC14 and olive oil, the mixture was administered in a volume of
2.0 to 3.0 mI/kg if body weight was less than that at the time of
previous injection. The control rats were injected with olive oil
only in the same manner. After all experiments were com-
pleted, the animals were killed to check the presence of ascites
and to examine histology of liver.
Oral water loading test
The animals were housed at room temperature of 21 to 23°C
with light on from 8:00 a.m. to 8:00 p.m. They were acclimated
to water and food two hours before the start of experiments.
The experiments were started two hours after the removal of
water and food. The rats were orally administered the vehicle
(water) or 5 mg/kg OPC-3 1260 in a volume of 3 ml/kg by gastric
tubes. Twenty minutes later they were given 30 mllkg of water
by gastric tubes under light ether anesthesia. The rats were
placed in individual metabolic cages (Natsume, Inc., Tokyo,
Japan) and allowed to awaken. Spontaneously voided urine
samples were collected at 20 minute intervals for three hours.
Urine volume (UV), urinary osmolality (Usm), urinary excre-
tion of sodium (UNa), and potassium (UK) were measured, and
the percent of water load excreted and the minimal U05m were
recorded. The dose of 5 mg/kg OPC-3 1260 was enough to block
the antidiuretic action of endogenous AVP [41, 421. Also, the
experiments were carried out in the same manner using the
peptide AVP antagonist, d(CH2)5DTyr(Et)VAVP, synthesized
by Manning et al [211. The antagonist was injected at a dose of
30 pg/kg intraperitoneally [31].
One milliliter of blood sample was collected from the tail
artery under light ether anesthesia a day before the start of
experiments and at the end of experiments. Serum osmolality
(5Osm), hematocrit (Hct), serum sodium, and potassium were
determined. Ssm and Usm were measured by freezing-point
depression (Model 3W2, Advanced Instrument, Needham
Heights, Massachusetts, USA).
Measurement of plasma AVP
Two groups of rats, cirrhotic rats and control rats, were
decapitated to collect blood samples under ad libitum water
drinking or 60 minutes after the oral water load (30 ml/kg) as
described earlier. This was chosen as our preliminary experi-
ments showed that the maximal urine volume and the minimal
Uosm occurred about 40 to 60 minutes after the oral water load.
These samples were centrifuged at 4°C at 3000 rpm for 15
minutes and plasma was frozen at —20°C until the time of assay.
Plasma AVP was measured by radioimmunoassay using AVP
Radioimmunoassay Kits (Mitsubishi Yuka, Tokyo, Japan) [31,
43].
Effect of d(CH2)5Tyr(Me)A VP on mean arterial pressure
After induction of anesthesia with ether, a catheter (PE-50,
Clay-Adams, Division of Becton, Dickinson & Co., Parsip-
pany, New Jersey, USA) was inserted into the left femoral
artery for monitoring blood pressure (Pressure transducer,
Model PAS-lOl, Star Medical Co., Tokyo, Japan; and Model
056 Recorder, Hitachi Electric Co., Tokyo, Japan). Another
catheter was inserted into the left femoral vein for drug admin-
istration. The rats were then placed in a restrainer (Shinnihon
Sangyo Co., Tochigi, Japan) and allowed to awaken. After
catheter insertion at least two hours were allowed before the
experiments were started. The baseline mean arterial pressure
(MAP) was monitored until stable for at least 30 minutes.
Thereafter, the vasopressor antagonist, [1 -(13-mercapto-13,13-
cyclopentamethyl enepropionic acid), 2-(O-methyl)-tyrosine]
AVP, d(CH2)5Tyr(Me)AVP (5 igIkg) or the vehicle (0.9%
saline) was injected intravenously in a volume of 0.4 ml [44, 45],
and then MAP was monitored for the next 60 minutes.
Effect of OPC-31260 on glomerular filtration rate
Under ether anesthesia catheters (PE-50, Clay-Adams) were
inserted into femoral artery and vein. A suprapubic catheter
(PE- 100) was inserted into the urinary bladder. The rats were
then placed in a restrainer (Shinnihon Sangyo) and allowed to
awaken and the experiments were started at least two hours
after the operation. The rats were infused with 0.9% saline
containing 3H-methoxy-inulin (specific activity, 345 mCilg;
NEN Products, Boston, Massachusetts, USA) at a rate of 0.5
mI/kg/mm (0.5 Ci/kg/min) using Harvard pump [31]. After 60
minutes, three 10-minute urine collections were made and then
a 0.5 ml blood sample was taken from the femoral artery.
Twenty minutes after the oral administration of 5 mglkg OPC-
31260, three 10-minute urine collections were made and a 0.5 ml
blood sample was taken again at the end of the experiments.
The concentrations of 3H-methoxy-inulin were determined us-
ing Liquid Scintillation Spectrometer (Model LSC-671, Aloka,
Tokyo, Japan). Inulin clearance was calculated as an index of
glomerular filtration rate (GFR) [311.
Statistics
All values of UV, Uosm, UNa, UK, body weight, Hct, Ssm,
SNa, SK, MAP, plasma AVP and GFR were analyzed by an
analysis of multiple variance and Student's t-test. A P value less
than 0.05 was considered significant.
Results
Light microscopic finding of liver stained with Azan is shown
in Figure 1. In the cirrhotic rats the lobular structure of liver
was totally destroyed and reconstituted by fibrotic tissues,
so-called pseudolobulus. In contrast, there was normal lobular
structure of liver in the control rats. All of the cirrhotic rats had
ascites in a volume of 0.4 to 11.0 ml (mean value, 2.5 ml).
Change in body weight in the cirrhotic rats and the control
rats is shown in Figure 2. Body weight gain during the three-
month observation period was significantly less in the cirrhotic
rats than that in the control rats. At 12 weeks, body weight was
252.2 10.5 g and 350.8 4.1 g in the cirrhotic rats and the
control rats, respectively. Hematocrit was lower in the cirrhotic
rats than the control rats (46.3 0.4 vs. 39.2 1.0%, N = 6, P
<0.01).
Figure 3 depicts the results of acute water loading test. The
upper panel shows the percent of water load excreted during the
three-hour observation period. Percent of water load excreted
was 62.5 2.4% in the cirrhotic rats, which was less than that
of 102.1 6.1% in the control rats (P <0.01). The cirrhotic rats
had impaired water excretion. The administration of 5 mg/kg
OPC-3 1260 increased UV in the cirrhotic rats, as the percent of
water load excreted rose to 215.1 6.4% after receiving 5
mg/kg OPC-3l260 from 62.5 2.4% (P < 0.01). Also, similar
results were obtained in the control rats (102.1 6.1 vs. 161.1




Fig. 1. Microscopic finding of liver of the cirrhotic rats (A) or control rats (B) after the administration of CCI4 or the vehicle was completed.
Azan-staining (x 100).
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Time, weeks
Fig. 2. Change in body weight in the cirrhotic rats and the control rats
during the 12 weeks observation period. Open circles (0) show the
control rats; closed circles (•) show the cirrhotic rats. < 0.01
compared with that of the control rats. Values are means 5EM, N =
6.
load excreted between the vehicle and the non-peptide AVP
antagonist OPC-3 1260 was more evident in the cirrhotic rats
than the control. Figure 3B shows the minimal Uosm after 30
mi/kg water load. The minimal Uosm in the cirrhotic rats
receiving the vehicle was higher than that in the control rats
(185.5 47.7 vs. 125.5 17.4 mOsmlkg H20, P < 0.01). The
administration of S mg/kg OPC-3l260 reduced the minimal
Uosm in the cirrhotic rats to 85.2 5.1 mOsm/kg H20 (P C
0.01).
Figure 4 depicts the effect of the peptide AVP antagonist
d(CH2)5DTyr(Et)VAVP on the percent of water load excreted
and the minimal Uosm in the cirrhotic rats and the control rats.
The percent of water load excreted was 54.8 4.4% in the
cirrhotic rats, which was less than that of 92.4 1 .9% in the
control rats (P C 0.01). Similar to the OPC-31260 study, the
administration of 30 tg/kg d(CH2)5DTyr(Et)VAVP markedly
increased UV in the cirrhotic rats, as the percent of water load
excreted rose from 54.8 4.4% to 269.3 20.8% after
receiving the peptide AVP antagonist (P C 0.01). Also, similar
results were obtained in the control rats (92.4 1.9% vs. 164.8
8.0%, P C 0.01). The minimal Uosm in the cirrhotic rats
receiving the vehicle was higher than that in the control rats (P
C 0.01). The difference in the minimal Uosm in the cirrhotic rats
between the vehicle and the peptide AVP antagonist was quite
evident (222.7 24.8 vs. 49.1 3.6 mOsm/kg H20, P C 0.01).
Furthermore, the minimal Uosm in the cirrhotic rats receiving
the peptide AVP antagonist was lower than that in the control
rats receiving the peptide AVP antagonist (P C 0.01).
Serum Na, 5K and 5Osm before and after the acute water load
in the cirrhotic rats and the control rats are shown in Table I.
Serum Na level was higher in the cirrhotic rats than that in the
control rats (P C 0.05). Serum Na level was reduced to 146.0
1.2 mEq/liter in the cirrhotic rats after the oral water load. The
oral administration of 5 mg/kg OPC-3 1260 markedly increased
serum Na levels. Quite similar results were obtained with 5Osm
Table 2 shows urinary excretions of Na and K in the cirrhotic
rats and the control rats. Urinary excretion of Na during the
three-hour observation period was 87.1 18.1 tEq in the

















Fig. 3. Effect of the non-peptide AVP antagonist OPC-31260 on per-
cent of water !oad excreted (A) and minima! Uogm (B) after an acute
water load (30 mI/kg) in the cirrhotic rats and the control rats. Open
bars show the control rats receiving the vehicle; solid bars show the
control rats receiving 5 mg/kg OPC-3 1260; hatched bars show the
cirrhotic rats receiving the vehicle; and cross-hatched bars show the
cirrhotic rats receiving 5 mg/kg OPC-3 1260. *3) < 0.01. Values are
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pEq in the control rats. The oral administration of 5 mg/kg
OPC-31260 significantly increased urinary excretion of Na by
2.2- and 4.4-fold in the control and the cirrhotic rats, respec-
tively. Urinary excretion of K was less in the cirrhotic rats than





Control Control LC LC
vehicle d(CH2)5D- vehicle d(CH2)5D-
Tyr(Et)VAVP Tyr(Et)VAVP
Fig. 4. Effect of the peptide AVP antagonist d(CH2)5DTyr(Et) VA VP
on percent of water load excreted (A) and minimal U0,,, (B) after an
acute water load (30 mI/kg) in the cirrhotic rats and the control rats.
Open bars show the control rats receiving the vehicle; solid bars show
the control rats receiving 30 pg/kg d(CH2)5DTyr(Et)VAVP; hatched
bars show the cirrhotic rats receiving the vehicle; and cross-hatched
bars show the cirrhotic rats receiving 30 /.Lg/kg d(CH2)5DTyr(Et) VA VP.
*D < 0.01. Values are means SEM, N = 7.
Table 1. Changes in serum Na, serum K, and serum osmolality
(So,m) before and after acute water load (30 ml/kg) in the cirrhotic
rats and the control rats
Control rats Cirrhotic rats
Before After Before After
Serum Na
mEqlliter
Vehicle 147.5 0.6 146.5 0.7 149.5 0.4 146.0 l.2a
OPC-31260 147.2 0.6 148.8 0.3a 149.7 0.4 154.7 0.6
Serum K
mEq/liter
Vehicle 5.1 0.1 4.5 0.la 4.4 0.1 3.9 0.2
OPC-31260 5.2 0.1 4.4 0.04 4.4 0.1 4.1 0.2
50sm mOsmi
kg
Vehicle 295.0 0.9 295.3 0.4 296.3 0.8 293.7 0.3a
OPC-31260 294.5 0.4 299.7 0.6k 296.7 0.7 305.7 l.8a
Values are means SEM, N = 6.
a p < 0.05 compared with that before the administration of 5 mg/kg
OPC-3 1260 or the vehicle
Table 2. Changes in urinary excretions of Na and K in the cirrhotic
rats and the control rats after the oral administration of 30 mI/kg
water
Urinary Na iEq/3 hr
5 mg/kg
Urinary K tEq/3 hr
5 mg/kg
Vehicle OPC-3 1260 Vehicle OPC-3 1260
rats
Cirrhotic 87.1 18.l' 387.4 82.0a,I 247.3 69.5 316.5 42.6'
rats
Values are means SEM, N = 6.
a P < 0.01 and b p < 0.05 compared with the vehicle group
P < 0.01 and d P < 0.05 compared with the control rats
that in the control rats. However, OPC-3 1260 did not affect the
urinary K excretion. Also, urinary urea excretion was less in
the cirrhotic rats than that in the control rats after the admin-
istration of OPC-31260 (22.8 5.1 vs. 43.5 4.1 mgI3 hr, P <
0.01).
When the rats were allowed free access to water, plasma
AVP level was 4.2 0.6 pg/ml in the cirrhotic rats, which was
higher than that of 1.7 0.1 pg/mi in the control rats (P < 0.01).
Plasma AVP level was reduced to only 2.4 0.5 pg/ml in the
cirrhotic rats 60 minutes after the oral water load. This was not
completely suppressed by the administration of water, because
this maneuver reduced plasma AVP level to 0.9 0.1 pg/mi in
the control rats (P < 0.05).
Baseline MAP were 114.8 1.8 and 113.7 2.3mm Hg in the
cirrhotic and the control rats, respectively, values not signifi-
cantly different between the two groups of rats. The adminis-
tration of 5 gig/kg d(CH2)5Tyr(Me)AVP, a V1 AVP antagonist,
did not alter MAP in the cirrhotic and the control rats (data not
shown).
The value of GFR in the cirrhotic rats was lower than that in
the control rats (2.2 0.2 vs. 2.9 0.1 ml/min, N = 6, P <
0.05). However, the administration of the antidiuretic antago-
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Discussion
Subcutaneous administration of CC!4 proved to be an effec-
tive procedure to induce liver cirrhosis in rats, which was
confirmed by histological study as shown in Figure 1. When the
maneuver lasted for more than three months, all of the rats
showed impaired water excretion and ascites. This means that
the cirrhotic rats injected with CC!4 fell into the state of
decompensation. The present maneuver of CC!4 injection
seems to be more promising to induce liver cirrhosis in rats as
compared to the CC14 inhalation reported previously [161, since
in our experience the induction rate of liver cirrhosis in rats was
not as high by the CCI4 inhalation method.
Decompensated liver cirrhosis in human and experimental
models of liver dysfunction have been noted to be associated
with impairment in water excretion [1—18]. The present results
provide strong evidence for a pathophysiological role of AVP in
the impaired water excretion in the decompensated state of
liver cirrhosis. The radioimmunoassayable plasma levels of
AVP were significantly elevated in the cirrhotic rats when
compared with that of the control rats. They were not suffi-
ciently suppressed by an acute oral water load, which sup-
pressed plasma AVP level in the control rats to less than 1
pg!ml. The elevation of plasma AVP levels in our cirrhotic rats
is in concert with those of previous reports. Previous reports
have shown that, in the decompensated cirrhotic patients and
animals, the plasma AVP levels were 2.1 to 4.2 pg/mI under ad
libitum water intake and 1.0 to 1.6 pg/ml after acute water load,
which were not sufficiently suppressed when compared with the
controls [2—5, 7, 16]. This elevation of plasma AVP level should
be associated with the non-osmotic stimulus. Previous studies
have demonstrated peripheral vasodilation, diminished plasma
oncotic pressure and splanchnic venous pooling in cirrhotic
patients and animals, which would provide the reduction in
effective blood volume [2—4, 7, 16].
To examine whether the elevated plasma AVP is involved in
the pathogenesis of the impaired water excretion in the cirrhotic
rats, we used the non-peptide antidiuretic antagonist, OPC-
31260, developed by Yamamura et al [40] and compared with
the effect of peptide AVP antagonist d(CH2)5DTyr(Et)VAVP
developed by Manning, Sawyer and their associates [211. Five
mg/kg OPC-3 1260 administered orally and 30 i.Lg/kg d(CH)5
DTyr(Et)VAVP administered intraperitoneally are sufficient to
inhibit the antidiuretic action of endogenous AVP [31, 41, 42].
After the administration of 5 mg/kg OPC-3 1260, the percent of
water load excreted in the cirrhotic rats exceeded over 200%,
which was significantly greater than the control rats. This was
not associated with the difference in osmolar clearance, be-
cause all of urinary excretions of Na, K and urea were less in
the cirrhotic rats than the control. The maximal urine flow was
apparently equal between both groups of rats, but in the late
stage urine flow was kept high in the cirrhotic rats as compared
to the control. Also, the administration of 5 mg/kg OPC-3 1260
diluted the minimal U0sm to less than 100 mOsmlkg H20 in the
cirrhotic rats, a value significantly lower than that in the
cirrhotic rats receiving the vehicle. We analyzed a direct
statistical comparison of the urine volume and the minimal
Uosm between OPC-3 1260 and d(CH2)5DTyr(Et)VAVP, using
the results shown in Figures 3 and 4. The urine volume was not
different in the control rats receiving 5 mg/kg OPC-31260 and 30
j.tg/kg d(CH2)5DTyr(Et)VAVP. However, the minimal Uosm of
both the cirrhotic and the control rats and the urine volume of
the cirrhotic rats were more evident after taking 30 tg/kg
d(CH2)5DTyr(Et)VAVP than after taking 5 mg/kg OPC-3 1260.
The antagonistic effect of 5 mg/kg OPC-3 1260 is a little weak as
compared to that of 30 pg/kg d(CH2)5DTyr(Et)VAVP. These
results indicate that endogenous plasma AVP plays an impor-
tant role in the pathogenesis of the impaired water excretion in
the cirrhotic rats. In addition, urinary Na excretion increased
after the oral administration of OPC-3 1260 in the present study.
As mentioned earlier, OPC-3 1260 is an aquaretic agent [401. In
fact, we found that OPC-3 1260 does not affect urinary Na
excretion in normal rats and in SIADH rats [41, 42]. OPC-3 1260
did not alter GFR, which may cause a change in urinary
excretion of Na. There is no adequate explanation about the
present peculiar finding.
The in vitro studies of Yamamura et a! [40] are that OPC-
31260 blocked the binding of [3H]AVP to the plasma membrane
preparations from rat kidney in a competitive manner. In
cultured rat renal papillary collecting tubule cells, OPC-3 1260
reduced the AVP-induced increase in cellular cyclic AMP
production in a dose-dependent manner [46]. Its maximal
inhibition was 61% of cellular cyclic AMP production stimu-
lated by AVP, which was weaker than the effect of the peptide
AVP antagonist d(CH2)5DTyr(Et) VA VP [46]. d(CH2)5DTyr
(Et)VAVP totally blocked the AVP-produced cellular cyclic
AMP in cultured rat renal papillary collecting tubule cells [46].
However, it is not critical to apply the in vivo antagonism to the
antidiuretic action of AVP, since OPC-31260 given orally
causes a marked water diuresis by antagonizing the antidiuretic
action of exogenous and endogenous AVP [41]. In addition, the
repeptive dosing of OPC-3 1260 does not cause a tachyphylaxis
[42].
The mean arterial pressure in the cirrhotic rats was compa-
rable to the level in the control rats, and the peptide V1 AVP
antagonist d(CH2)5Tyr(Me)AVP did not alter mean arterial
pressure in the cirrhotic rats at all. The present results indicate
that endogenous AVP does not exert a vascular effect to
maintain blood pressure, though we did not exclude counter-
regulatory increases in catecholamines and angiotensin II to
maintain blood pressure. The plasma AVP level was 4.2 pg/ml
under ad libitum water intake in the cirrhotic rats, a value not
sufficient to cause vascular action of AVP, as in normal rats a
plasma AVP level of more than 20 pg/ml is expected to affect
blood pressure, even if a pathological state of more than 10
pglml of plasma AVP levels is suggested [44, 47, 48].
In conclusion, the cirrhotic rats were made by the chronic
subcutaneous administration of carbon tetrachloride. The use
of a potent antagonist to the antidiuretic action of AVP showed
a predominant role of AVP in the impaired water excretion in
the decompensated cirrhotic rats. The present results indicate
that the unsuppressible secretion of AVP is involved in the
impaired water excretion in the decompensated cirrhotic rats.
Also, the therapeutic efficacy of an orally effective, non-peptide
AVP antagonist OPC-3 1260 to improve water retention in the
decompensated state of liver cirrhosis is expected.
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